Vera Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vera Therapeutics, Inc. on June 12, 2024, reporting events that occurred on June 7, 2024. The Company is a Delaware corporation with its principal executive offices in Brisbane, California, and its Class A common stock trades on The Nasdaq Stock Market LLC under the symbol "VERA".
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and executive compensation matters.
Material Changes
The primary material change reported is the appointment of Christy Oliger to the Board of Directors, effective June 7, 2024. Key details of this appointment include:
- Board Role: Ms. Oliger serves as a Class III Director with an initial term expiring at the 2027 Annual Meeting of Stockholders.
- Committee Assignment: Appointed to the Nominating and Corporate Governance Committee.
- Initial Equity Grant: Granted a nonstatutory stock option to purchase 25,000 shares of Class A common stock, vesting monthly over three years contingent on continuous service.
- Annual Compensation: Entitled to an annual cash retainer of $40,000 for Board service and $4,000 for Nominating Committee service (pro-rated for 2024).
- Future Equity Eligibility: Commencing with the 2025 Annual Meeting, eligible for annual option grants of the lesser of 14,000 shares or a grant date fair value of $400,000.
- Prior Service Compensation: Granted 2,987 restricted stock units (RSUs) for consulting services provided prior to her election. These RSUs are fully vested as to service and will settle in 2025.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The document confirms there are no related person transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the vesting schedule and exercise terms of the 25,000-share option grant to Ms. Oliger.
- Confirm the settlement date for the 2,987 RSUs granted for prior consulting services.
- Review the Company's Amended and Restated Non-Employee Director Compensation Policy for details on future annual grants.
- Check subsequent filings for any changes to the Board composition or compensation structure.